Long-lasting effect of cyclosporin-A on anemia associated with idiopathic myelofibrosis

Chair of Hematology DIMI, University of Genoa, Italy. Some reports suggest that immunologic mechanisms may play a role in the pathogenesis of anemia in idiopathic myelofibrosis (IMF). Herein we report the case of a transfusion dependent IMF patient with psoriasis in whom cyclosporin-A (CyA) treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 1997-07, Vol.82 (4), p.458-459
Main Authors: Pietrasanta, D, Clavio, M, Vallebella, E, Beltrami, G, Cavaliere, M, Gobbi, M
Format: Article
Language:English
Subjects:
Aged
Anemia - complications
Anemia - drug therapy
Biological and medical sciences
Cyclosporine - administration & dosage
Humans
Immunomodulators
Immunosuppressive Agents - administration & dosage
Male
Medical sciences
Pharmacology. Drug treatments
Primary Myelofibrosis - complications
Primary Myelofibrosis - drug therapy
Time Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chair of Hematology DIMI, University of Genoa, Italy. Some reports suggest that immunologic mechanisms may play a role in the pathogenesis of anemia in idiopathic myelofibrosis (IMF). Herein we report the case of a transfusion dependent IMF patient with psoriasis in whom cyclosporin-A (CyA) treatment for skin lesions (200 mg/day) was associated with long-lasting correction of anemia. After 2 months of CyA therapy the patient's Hb level increased and he became transfusion free in 4 months. After 12 months immunosuppressive therapy was discontinued due to renal toxicity, yet the Hb level remained stable for an additional 12 months. The patient is currently being administered CyA at a reduced dosage because of mild renal impairment along with transfusional support consisting of a median of 2 red cell units/month. Altogether the patient received no transfusional support for 36 months. This case, as well as other reports, suggests that the issue of immunosuppressive treatment in IMF anemia deserves further investigation.
ISSN:0390-6078
1592-8721